Opinion Formers' Conference on Counterfeit Medicines

Click here to read the full article as an Adobe Acrobat PDF.

Medicines have to pass through a rigorous series of clinical trials to prove their efficacy and safety. Once licensed, production is stringently regulated to ensure that drugs are manufactured to a uniformly high quality. These systems are essential if patients are to have confidence in the medicines they are prescribed. By bypassing these systems, the manufacturers of counterfeit medicines are not only illegally profiting from others' endeavours--they are also putting patients' lives at risk.

Counterfeits have been of concern ever since medicinal products were first used. Shortly after cinchona bark was introduced as a treatment for malaria in the 17th century, adulteration with other barks undermined public confidence. Similarly, when its active ingredient, quinine, was produced in the early 1800s, it too was counterfeited. The US government accused Britain of supplying fake quinine as an underhand ploy to sabotage the USA's war with Mexico.

In 1913, Carl Alsberg of the US Bureau of Chemistry launched "a stubborn campaign against fraudulent patent medicines". He said: "Fake drugs do incalculable harm to the misguided sick, who grasp at the false hopes they hold on to." Concern about trade in counterfeit medicines thus has a long history. In the modern era, it has evolved into an organised global criminal industry worth billions of dollars.

Roger Bate is the Legatum Fellow in Global Prosperity at AEI. Brian Ellliott is the executive director of the Medicines Transparency Alliance Secretariat. Ron Guido is the vice president of Global Brand Protection at Johnson and Johnson. Julian Harris is a research fellow at the International Policy Network. Hans Hogerzeil is the director of essential medicines and pharmaceutical policies at the World Health Organization. Paul Newton is the head of the Wellcome Trust-Mahosot Hospital-Oxford Tropical Medicine Research Collaboration in Laos. Aline Plancon is the INTERPOL-IMPACT project manager at INTERPOL, Andrew Jack is the pharmaceuticals correspondent to the Financial Times, Michael Boyd is the director general of the International Federation of Pharmaceutical Manufacturers and Associations, Geneva, and vice president of public affairs internations at the Schering-Plough Corporation. William Castell is the chairman of the Wellcome Trust. Pedro Velasco Martins is the principal administrator in charge of IPR Enforcement at the European Commission DG for Trade. Mark Walport is the director of the Wellcome Trust. Hashim Yusufu is the director of enforcement at the National Agency for Food and Drug Administration and Contol in Nigeria.

Click here to read the full article as an Adobe Acrobat PDF.

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

Roger
Bate

What's new on AEI

Obama should channel Reagan on Russia
image Tackling our nation’s budget problems, head on
image Missing the point on inversions and corporate taxes
image Venezuela betrayed — missed chance to expose regime
AEI on Facebook
Events Calendar
  • 28
    MON
  • 29
    TUE
  • 30
    WED
  • 31
    THU
  • 01
    FRI
Tuesday, July 29, 2014 | 10:00 a.m. – 12:00 p.m.
Is Medicare's future secure? The 2014 Trustees Report

Please join AEI as the chief actuary for Medicare summarizes the report’s results, followed by a panel discussion of what those spending trends are likely to mean for seniors, taxpayers, the health industry, and federal policy.

Event Registration is Closed
Friday, August 01, 2014 | 10:30 a.m. – 12:00 p.m.
Watergate revisited: The reforms and the reality, 40 years later

Please join us as four of Washington’s most distinguished political observers will revisit the Watergate hearings and discuss reforms that followed.

No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.